Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | HAO1 | Q9UJM8 | 5/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4734047 | 0.89 | BACE1 (0.43) | BACE1HAO1CARM1PRMT6CYP1A2 | |
| SCHEMBL7367004 | 0.85 | SLC22A12 (0.47) | HAO1RAB9ANAPRTGRM4 | |
| SCHEMBL30728620 | 0.80 | EZH2 (0.50) | — | |
| SCHEMBL4735355 | 0.79 | ADRB1 (0.41) | CARM1PRMT6RAB9ANAPRTPPARG | |
| SCHEMBL4734100 | 0.78 | MAPK8 (0.46) | RAB9A | |
| SCHEMBL6460814 | 0.77 | CARM1 (0.52) | CARM1PRMT6CYP1A2CYP2C19RAB9A | |
| SCHEMBL29719546 | 0.76 | KMT2A (0.56) | BACE1CYP1A2CYP2C9CYP2C19ALOX5AP | |
| SCHEMBL20523025 | 0.74 | DHODH (0.47) | BACE1NAPRTPPARGADRB1ADRB3 | |
| SCHEMBL7454153 | 0.74 | PPARG (0.48) | CYP1A2CYP2C19RAB9APPARG | |
| SCHEMBL3293477 | 0.74 | ALDH1A1 (0.55) | CYP1A2CYP2C9CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008057280-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | TIE1, FLT4, CDK1 | BACE1 1949/4885HAO1 4252/4885CARM1 1538/4885 |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | TIE1, AURKB, TEK | BACE1 2886/4885HAO1 4182/4885CARM1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.